All In Biotech

Drug Trial Radar · NCT03564509

A Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation.

A Randomised, Double-blind, Placebo-controlled, Parallel-group, Dose-range Trial to Investigate the Efficacy and Safety of FE 999302 as add-on Treatment to Follitropin Delta (REKOVELLE) in Women Undergoing Controlled Ovarian Stimulation in a Long GnRH Agonist Protocol

Last checked: Nov 20, 2026Latest source record: Aug 31, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 620 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

620

Actual

Start

May 14, 2018

Primary completion

Oct 21, 2019

Study completion Jan 8, 2020

Sponsor

Lead sponsor
Ferring PharmaceuticalsIndustry
Sponsor type
Industry
First posted
Jun 21, 2018

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
Female only, from 30 years, up to 42 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this phase 2 dose-ranging trial is to investigate the effects of FE 999302 on parameters influencing pregnancy rates in women undergoing Controlled Ovarian Stimulation (COS) with follitropin delta in a long gonadotropin releasing hormone (GnRH) agonist protocol. Furthermore, the study intends: * To investigate the safety of FE 999302 in women undergoing COS with follitropin delta in a long GnRH agonist protocol. * To investigate the potential immunogenicity of FE 999302 in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol. * To estimate the impact of body weight on FE 999302 exposure in subjects undergoing COS with follitropin delta in a long GnRH agonist protocol.

Conditions

  • Controlled Ovarian Stimulation

Interventions

  • FE 999302 (1 μg) and follitropin deltaDrug

    Daily dose of 1 μg of FE 999302, a recombinant human chorionic gonadotropin (rhCG) solution for subcutaneous injection; individualized follitropin delta dose.

  • FE 999302 (2 μg) and follitropin deltaDrug

    Daily dose of 2 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

  • FE 999302 (4 μg) and follitropin deltaDrug

    Daily dose of 4 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

  • FE 999302 (8 μg) and follitropin deltaDrug

    Daily dose of 8 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

  • FE 999302 (12 μg) and follitropin deltaDrug

    Daily dose of 12 μg of FE 999302, a rhCG solution for subcutaneous injection; individualized follitropin delta dose.

  • Placebo and follitropin deltaOther

    Daily dose of placebo; individualized follitropin delta dose.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of good-quality blastocysts on Day 5 after oocyte retrievalTime frame: On Day 5 after oocyte retrieval

Locations

20 sites in 5 countries. Site status is shown where the registry gives one.

  • Universitair Ziekenhuis Gent (UZ Gent)

    Ghent, Belgium

  • Universitair Ziekenhuis Brussel

    Jette, Belgium

  • Institut fur Reproduktionsmedizin und Genetik

    Karlovy Vary, Czechia

  • Fertimed

    Olomouc, Czechia

  • GYNEM

    Prague, Czechia

  • IVF CUBE

    Prague, Czechia

  • Aalborg University Hospital

    Aalborg, Denmark

  • Rigshospitalet

    Copenhagen, Denmark

  • Dansk Fertilitetsklinik

    Frederiksberg, Denmark

  • Hvidovre Hospital

    Hvidovre, Denmark

  • Dexeus Woman's Health

    Barcelona, Spain

  • Instituto Valenciano de Infertilidad (IVI) - Bilbao

    Leioa, Spain

  • GINEFIV - Clinica Belen Location

    Madrid, Spain

  • Instituto Valenciano de Infertilidad (IVI) - Madrid

    Madrid, Spain

  • Instituto Valenciano de Infertilidad (IVI) - Sevilla

    Seville, Spain

  • Instituto Valenciano de Infertilidad (IVI) - Valencia

    Valencia, Spain

  • Glasgow Royal Infirmary

    Glasgow, United Kingdom

  • Liverpool Women's Hospital

    Liverpool, United Kingdom

  • Guy's and St Thomas' NHS Trust

    London, United Kingdom

  • Kings College (Assisted Conception Unit)

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.